"On the forefront of diagnostic challenges of tomorrow"

Technoclone Herstellung von Diagnostika und Arzneimitteln  GmbH was founded in 1987 by Prof. Dr. Bernd R. Binder (1945 - 2010). The main focus of the company was on monoclonal antibodies against components of the coagulation and the fibrinolytic systems. Technoclone was worldwide the first company offering a complete set of ELISAs and of a novel patented system allowing determination of activity and antigen in the same sample (Actibind) in the field of fibrinolysis.

Acquisition of the former Immuno diagnostics portfolio from the Baxter AG

From 1998 on Technoclone expanded rapidly through the acquisition of the former Immuno diagnostics from Baxter AG and the establishment of an distribution system all over the world.

Production and OEM Products

Technoclone is a world-leading producer of diagnostics tests, equipment and research products in the area of haemostasis and fibrinolysis. Next to a complete test portfolio in routine and specialty testing Technoclone has improved their fully automated Ceveron alpha / alpha TGA instruments to the new Ceveron 100 Series instrument line. With more than 10 years of experience of fully automated Thrombin Generation testing, the new Ceveron 100 series instruments have increased the TGA testing capacity by 50% . Additionally using the quenching technology on the top line system the Ceveron s100, Technoclone offers the first fully automated haemostasis analyzer worldwide which is able to run routine and specialty testing out of one sample simultaneously, including Thrombin Generation, ADAMTS13 activity and Factor XIII activity fully automated.

Technoclone´s high quality in vitro diagnostics and test systems are sold worldwide not only under the Technoclone label but are also found as OEM products in the catalogues of international diagnostics companies.

Research & Development

The focus of Technoclone´s research and development is in the field of thrombosis and cardiovascular diseases, the world leading cause of mortality and morbidity. Research and development is pursued in Technoclone´s own research division and in close cooperation with Universities and international and national research consortia. Technoclone holds at present more than 10 international patents in the field of diagnosis and therapy of vascular diseases.